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Synthesis, Radio-Synthesis and in vitro Evaluation of Terminally 
Fluorinated Derivatives of HU-210 and HU-211 as Novel Candidate 
PET Tracers  
Chiara Zanato,a,* Alessia Pelagalli,a Katie F. M. Marwick,b Monica Piras,a Sergio Dall’Angelo,a 
Andrea Spinaci,a Roger G. Pertwee,a David J. A. Wyllie,b Giles E. Hardingham,b Matteo Zandaa,c,* 
We report the synthesis of terminally fluorinated HU-210 and HU-211 analogues (HU-210F and HU-211F, respectively) and 
their biological evaluation as ligands of cannabinoid receptors (CB1 and CB2) and N-methyl D-aspartate receptor (NMDAR). 
[18F]-labelled HU-210F was radiosynthesised from the bromo-substituted precursor. In vitro assays showed that both HU-
210F and HU-211F retain the potent pharmacological profile of HU-210 and HU-211, suggesting that [18F]-radiolabelled 
HU-210F and HU-211F could have potential as PET tracers for in vivo imaging.
Introduction 
 
Cannabinoid receptors – CB1 and CB2 – are involved in 
psychiatric, neurological, and behavioural disorders, as well as 
in non-CNS pathologies such as liver fibrosis, metabolic 
disorders such as diabetes, and cancer. PET imaging has 
emerged as a powerful technology for the diagnosis and 
staging of CNS and non-CNS pathologies, as well as a tool in 
drug design and development. We and others have actively 
investigated novel cannabinoid-ligands as PET tracers,1 
however few [18F]-labelled tracers have demonstrated true 
potential to image cannabinoid receptors in vivo. 
Recently, Kassiou et al. have shown that synthetic cannabinoid 
ligands carrying a terminal fluorine atom on linear aliphatic 
chains have superior or equivalent pharmacological properties 
relative to non-fluorinated counter-parts.2 This observation 
supported our idea to investigate novel selectively fluorinated 
cannabinoid analogues as candidate PET tracers, in particular 
HU-210 (Fig. 1) which is a potent (–)-1,1-dimethylheptyl 
analogue of 11-hydroxy-Δ8-tetrahydrocannabinol.3 This 
cannabinoid receptor agonist was reported to have 0.061 and 
0.52 nM Ki values at cloned human CB1 and CB2 receptors, 
respectively. HU-210 also displays agonist activity at GPR55 
(EC50 = 26 nM). Interestingly, its enantiomer HU-211 
(dexanabinol, Fig. 1) has very different pharmacological 
properties, being essentially inactive as a cannabinoid but 
active as N-methyl D-aspartate receptor (NMDAR) ligand (IC50 
= 11 μM for inhibition of [3H]MK-801 binding to rat forebrain 
membranes).4 HU-211 has been shown to have 
neuroprotective effects and is being clinically tested for 
treating traumatic and ischemic brain injury. HU-211 is also an 
effective free radical scavenger, and is currently in phase-II 
clinical trials for the therapy of solid tumours.5 
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Figure 1 Natural cannabinols, analogues and radioactive derivative. 
Despite the strong interest in HU-210 and HU-211, to our 
knowledge the use of radiolabelled analogues for in vivo 
imaging has never been reported, and fluorinated analogues 
have not been described either.  
We hereby report a synthesis of terminally fluorinated HU-210 
and HU-211 analogues, namely HU-210F and HU-211F (Fig. 1), 
we demonstrate that both compounds maintain their original 
pharmacological properties in vitro. Finally we describe the 
radio-synthesis of [18F]HU-210. These results will enable the 
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use of these compounds as PET tracers for in vivo imaging 
studies. 
 
 
 
Scheme 1 Retrosynthetic approach to (–)-(R,R)-HU-210F and (+)-(S,S)-HU-211F.
Results and discussion 
Synthesis of (–)-(R,R)-HU-210F and (+)-(S,S)-HU-211F 
The retrosynthetic approach to the target compounds (–)-(R,R)-HU-
210F and (+)-(S,S)-HU-211F (Scheme 1) was inspired by the 
chemistry published by Zahalka6 and Huffman.7 Fluorinated 
resorcinol 1 was identified as a key intermediate to be reacted 
with both enantiomers of 4-hydroxy-myrtenyl pivalate 2a,b 
forming the desired THC-like structural frameworks. Synthesis 
of the key fluorinated building block 1 proved to be 
challenging. In fact, a number of unsuccessful approaches to 1 
were attempted (more information is provided in the 
Electronic Supporting Information section) before identifying a 
successful synthetic strategy (Scheme 2). The synthesis of 1 
started with the methylation8 of commercially available (3,5-
dimethoxyphenyl)acetonitrile (3), that afforded the α,α-
dimethylnitrile 4 in excellent yield. Subsequent hydride 
reduction9 of 4 afforded the aldehyde 5, which was subjected 
to a Wittig olefination9 with the ylide generated10 from the 
phosphonium salt 6 that yielded the unsaturated alcohol 7 as a 
single isomer, presumably having (Z)-geometry. The C=C bond 
of 7 was then hydrogenated (Pd/C, H2, in EtOAc)
9 to give 
compound 8 in quantitative yield. During a first O-
demethylation attempt (BBr3 in DCM from -78°C to -10 °C)
11 an 
undesired replacement of the primary OH of 8 with a Br atom 
occurred, leading to the corresponding alkyl bromide. 
However, treatment of 8 with MeMgI at 170°C12 provided the 
demethylated alcohol 9 in very good yield. Next, 9 was 
dehydroxyfluorinated with DAST13 (the use of DEOXOFLUOR 
provided lower yields) affording the target building block 1. 
The synthesis of (–)-(R,R)-HU-210F (Scheme 3) was achieved 
from commercially available (–)-(1R)-Myrtenol (≥95% ee) that 
was transformed into 4-hydroxy-myrtenyl pivalate 2a using the 
method of Zahalka and Huffman.6,7 The synthesis of (+)-(S,S)-
HU-211F (Scheme 3) was achieved from commercially 
available (+)-(α)-Pinene (≥99% ee), that was first transformed 
into the corresponding (+)-(1S)-Myrtenol by means of an allylic 
oxidation promoted by SeO2,
14 and then converted into 2b. 
The common intermediate 1 was condensed with 2a or 2b in 
the presence of BF3
.Et2O at -20°C, affording the protected 
esters 10a and 10b, respectively. 
 
Scheme 2 Synthesis of common intermediate 1. Reagents and 
conditions: i) NaH, MeI, DMF, 0°C to rt, 2h (98%); ii) DIBALH, DCM, rt, 
1h (93%); iii) LiHMDS, THF, 0°C to rt, on (92%); iv) H2 (1 atm), 10% 
Pd/C, EtOAc, on (quantitative); v) MeMgI, Et2O/THF, 0°C to 170°C, 1h 
(70%); vi) DAST, DCM, -78°C, 0°C, 15 min (50%). 
Finally, reduction with LiAlH4 gave the target fluorinated 
compounds (–)-(R,R)-HU-210F and (+)-(S,S)-HU-211F. Since the 
source of chirality in the syntheses are the two 4-hydroxy-
myrtenyl pivalate enantiomers, 2a and 2b, the ee of the two 
final compounds reflected the ee of the commercially available 
starting materials (≥95% ee for 2a and ≥99% ee for 2b).The 
enantiomeric purity of the cannabinoids mimics was confirmed 
by analytical chiral HPLC. Subsequently (–)-(R,R)-HU-210F and 
(+)-(S,S)-HU-211F were purified by semi-preparative chiral 
HPLC in order to obtain high-purity (>99% ee) single 
enantiomers for the pharmacological assays (see the 
Experimental for details). 
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Scheme 3 Synthesis of (_)-(R,R)-HU-210F and (+)-(S,S)-HU-211F. 
Reagents and conditions: i) BF3
.Et2O, DCM, -20°C to rt, 2h (55%); ii) 
LiAlH4, THF, 0°C, 2h (50%). 
Biological tests on CB1 and CB2 receptors 
We performed [3H]CP55940 displacement binding assays with 
membranes obtained from hCB1 and hCB2 CHO cells using 
methods we have described previously.15 (–)-(R,R)-HU-210F 
and (+)-(S,S)-HU-211F each shared the ability of the established 
CB1/CB2 receptor agonist CP55940 to induce a full 
displacement of [3H]CP55940 from binding sites on both 
human CB1 and human CB2 CHO cell membranes (Figures 2 and 
3). (–)-(R,R)-HU-210F displayed similar affinities for these CB1 
and CB2 binding sites, as did (+)-(S,S)-HU-211F. It was also 
found, however, that (–)-(R,R)-HU-210F showed significantly 
greater potency than (+)-(S,S)-HU-211F at displacing 
[3H]CP55940 both from CB1 and from CB2 binding sites (Table 
1). As expected for such potency differences, the 
corresponding CB1 and CB2 Ki values of (–)-(R,R)-HU-210F were 
each found to be less than the CB1 and CB2 Ki values of (+)-(S,S)-
HU-211F (Tables 1). 
Biological tests on NMDA receptors 
To assess the ability of (–)-(R,R)-HU-210F and (+)-(S,S)-HU-211F 
to antagonise NMDAR we made whole-cell patch-clamp 
recordings from primary rat cultured cortical neurons. Neurons 
were clamped at -60 mV and NMDA (50 µM) applied to evoke 
a current that was mediated predominantly by diheteromeric 
GluN1/GluN2B NMDARs.16 Once a steady-state response was 
observed, we co-applied each compound of interest and 
assessed the percentage reduction in current (Fig. 4). To 
control for desensitisation of response during continued 
agonist exposure, we also applied NMDA with vehicle alone 
(1% DMSO) (Fig. 4A). We found that (–)-(R,R)-HU-210F showed 
no NMDAR antagonism when compared to vehicle alone (Fig. 
4B, F). In contrast, (+)-(S,S)-HU-211F gave a maximal block of 
around 80% at the concentration used (Fig. 4C, F). In addition, 
we compared NMDAR antagonism of the parent compound, 
(+)-(S,S)-HU-211, which we found blocked NMDAR-mediated 
currents to an extent not significantly different from that seen 
with (+)-(S,S)-HU-211F (Fig. 4D, F). We noted a slow blocking 
on-rate with both (+)-(S,S)-HU-211 and (+)-(S,S)-HU-211F 
which was not due to slow rates of perfusion as MK-801 (a 
NMDAR open channel blocker which binds at a similar site) 
blocked NMDAR-mediated responses rapidly (Fig. 4E). 
 
Figure 2 Effects of (A) HU-210F (n=5), (B) HU-211F (n=7) and (C) 
CP55940 (n=7) on [3H]CP55940 binding to human CB1 CHO cell 
membranes. 
 
Figure 3 Effects of (A) HU-210F (n=5), (B) HU-211F (n=5) and (C) 
CP55940 (n=6) on [3H]CP55940 binding to human CB2 CHO cell 
membranes. 
These experiments assessing NMDAR antagonism confirmed 
that (+)-(S,S)-HU-211 is a NMDAR antagonist and that its 
potency is retained in its fluorinated form (+)-(S,S)-HU-211F 
(Table 2). The finding that (+)-(S,S)-HU-211 is an NMDAR 
antagonist is consistent with previous work using radioligands, 
behavioural assays, excitotoxicity assays and calcium influx.17 
Based on the previously reported IC50 of 11 µM,
17b we would 
have predicted a more complete block at the concentration 
used here (100 µM). 
However, this IC50 was based on radioligand studies assessing 
displacement of MK-801 whereas our work is the first 
electrophysiological assessment of the effect of (+)-(S,S)-HU-
211. Using electrophysiology to assess the effect of (+)-(S,S)-
HU-211 and its fluorinated analogue (+)-(S,S)-HU-211F has also 
allowed us to highlight their very slow on-rate, a property not 
identified previously. 
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Compound Membrane Mean EC50 nM (95% CL) Mean Emax % (95% CL) Mean Ki nM (95% CL) 
(–)-(R,R)-HU-210F 
hCB1 CHO cells 
hCB2 CHO cells 
1.63 (1.25-2.14) 
4.46 (316-6.28) 
107.5 (103.5-111.5) 
102.3 (98.9-105.8) 
0.98 (0.76-1.31) 
3.83 (2.72-5.40) 
(+)-(S,S)-HU-211F 
hCB1 CHO cells 
hCB2 CHO cells 
222.7 (149.8-331.1) 
480.4 (281.2-820.7) 
108.8 (101.4-116.2) 
108.2 (97.25-119.2) 
136.1 (91.53-202.3) 
413.1 (241.8-705.8) 
CP55940 
hCB1 CHO cells 
hCB2 CHO cells 
5.87 (4.00-8.61) 
14.17 (9.83-20.42) 
96.39 (91.1-101.7) 
100.1 (93.71-106.5) 
3.59 (2.45-5.26) 
12.18 (8.45-17.56) 
Table 1 Mean Ki, Emax and EC50 values of HU-210F, HU-211F and the control molecule CP55940 on hCB1 CHO and hCB2 CHO membranes. 
 
Figure 4 (+)-(S,S)-HU-211F and (+)-(S,S)-HU-211 are both NMDAR 
antagonists. (A-E) Example whole-cell current recordings from rat 
cortical neurons. (A) NMDA (50 µM) with vehicle (1% DMSO), 
demonstrating desensitisation (mean percentage reduction in current 
compared to NMDA alone 8.7 ± 5.9 (n=7 cells)). (B) NMDA co-applied 
with (–)-(R,R)-HU-210F (100 µM), showing no additional block 
compared to vehicle (10.8 ± 17.5 (6), p =0.995 ). (C) NMDA co-applied 
with (+)-(S,S)-HU-211F (100 µM), showing significant block compared 
to vehicle (79.2 ± 15.8% (8), p<0.0001)). (D) NMDA co-applied with (+)-
(S,S)-HU-211 (100 µM), showing significant block compared to vehicle 
(61.6 ± 13.9% (6), p<0.0001) but not significantly different to (+)-(S,S)-
HU-211F (p=0.115). (E) NMDA co-applied with MK-801 (10 µM), 
demonstrating faster on rate and 100% block. Scale bar applies to all 
traces. (F) Summary data. Data represent mean ± SEM. Mean 
percentage inhibition of NMDAR-mediated currents for vehicle alone 
and the three compounds of interest were first compared using a one 
way ANOVA, which showed a significant effect of compound (F(3,23) = 
46.9, p<1E-9). We then compared individual means using post-hoc 
Tukey t-tests. *** p<0.001. 
 
 
 
 
Compound Inhibition of NMDAR current (%) 
[mean ± SD (n)] 
(–)-(R,R)-HU-210F 10.8 ± 17.5 (6) 
(+)-(S,S)-HU-211F 79.2 ± 15.8 (8) 
DMSO 8.7 ± 5.9 (7) 
(+)-(S,S)-HU-211 61.6 ± 13.9 (6) 
Table 2 Inhibition of NMDAR current by (–)-(R,R)-HU-210F, (+)-(S,S)-
HU-211F, DMSO and (+)-(S,S)-HU-211. 
However, this IC50 was based on radioligand studies assessing 
displacement of MK-801 whereas our work is the first 
electrophysiological assessment of the effect of (+)-(S,S)-HU-
211. Using electrophysiology to assess the effect of (+)-(S,S)-
HU-211  and its fluorinated analogue (+)-(S,S)-HU-211F has 
also allowed us to highlight their very slow on-rate, a property 
not identified previously. 
 
Radio-Synthesis of (–)-(R,R)-[
18
F]HU-210 
The synthesis of radiofluorinated (–)-(R,R)-[18F]HU-210 was 
addressed next. As a radiosynthesis precursor, we opted for 
the bromo-analogue of HU-210F, which was synthesised both 
in di-acetylated form 14a and hydroxyls-free form 14b 
(Scheme 4). 
The starting alcohol 8 was subjected to the Appel reaction 
leading to the corresponding alkyl bromide 11 that was first O-
demethylated11 to give the substituted resorcinol 12 and, then, 
reacted with myrtenyl acetate 2c (obtained from commercially 
available (–)-(1R)-Myrtenol as described in the Electronic 
Supporting Information section) to give the mono-acetylated 
bromo-derivative 13. From this common intermediate we 
synthesised both 14a and 14b, via O-acetylation and basic 
hydrolysis, respectively 
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Scheme 4 Synthesis of precursors 14a and 14b. Reagents and 
conditions: i) CBr4, PPh3, CH3CN, 0°C to rt, 1h (90%); ii) BBr3, DCE, rt, 
1.5h (82%); iii) BF3
.Et2O, DCM, -20°C to rt, 2h (20%); iv) Acetyl chloride, 
TEA, DCM, rt. 1h (quantitative); vii) NaOH, CH3CN, 36°C, 4h 
(quantitative). 
 
The radio-synthesis of (–)-(R,R)-[18F]HU-210 (Scheme 5) was 
then attempted from both 14a,b by nucleophilic substitution 
of the bromine atom with the [18F]KF 2.2.2 Kriptofix® complex.  
(_)-(R,R)-[18F]HU-210
OAc
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Scheme 5 Radio-synthesis of (–)-(R,R)-[18F]HU-210. Reagents and 
conditions: i) [18F]KF 2.2.2 Kryptofix®, CH3CN, 100 °C, 15 min.; ii) NaOH 
4M, 50 °C, 10 min 
Using the di-acetylated derivative 14a, the radio-fluorination 
was not successful, since complete and rapid degradation of 
the starting material was observed. However, 14b was 
successfully radio-fluorinated to (–)-(R,R)-[18F]HU-210 with a 
preliminary 6% radio-chemical conversion (evaluated by Radio-
HPLC) using a non-optimised automated procedure in a 
remotely controlled modular reactor system. Identity of the 
tracer was confirmed by co-injection with the cold reference 
compound. 
 
Figure 5 Radio-HPLC Chromatogram of the crude mixture after 15 min 
labelling. 
 
The same method could be used to produce (+)-(S,S)-[18F]HU-
211. 
Conclusions 
Terminally fluorinated analogues of the potent cannabinoid 
receptor ligand (–)-(R,R)-HU-210 and its enantiomer (+)-(S,S)-
HU-211, which is an NMDAR antagonist, were efficiently 
synthesised. In vitro biological evaluations of (–)-(R,R)-HU-210F 
and (+)-(S,S)-HU-211F showed that both analogues retain the 
original pharmacological profiles. The non-optimised radio-
synthesis of [18F]HU-210 from the bromo-precursor 14b was 
achieved as a proof-of-concept for demonstrating the 
feasibility of this method for enabling in vivo PET imaging 
studies. Although HU-210F is a non-selective ligand for CB-
receptors (Ki = 0.98nM for CB1 and 3.83nM for CB2), its very 
high affinity is in the classical range for enabling PET imaging 
studies. Therefore (–)-(R,R)-[18F]HU-210 could be used either 
for overall mapping and observation of CB-receptors 
distribution and occupancy (mostly central for CB1 and 
peripheral for CB2), or for selective blocking and competition 
experiments by co-administration with either CB1 or CB2-
specific ligands. The low CB and NMDA receptors affinity of (+)-
(S,S)-[18F]HU-211 is likely to preclude its use for in vivo imaging 
of these receptors, but this tracer could still represent a useful 
tool for investigating bio-distribution and mechanism of action 
of the parent anticancer drug dexanabinol, which is currently 
in advanced clinical trials. 
Experimental 
Biological tests on CB1 and CB2 receptors 
CHO cells 
Chinese hamster ovary (CHO) cells transfected with cDNA 
encoding human cannabinoid CB1 or CB2 receptors were 
maintained at 37 °C in Dulbecco’s modified Eagle’s medium 
nutrient mixture F-12 HAM, supplemented with 1 mM L-
glutamine, 10% fetal bovine serum, 0.6% penicillin–
streptomycin and G418 (400 mg/mL). All cells were exposed to 
5% CO2 in their respective media, and were passaged twice a 
week using non-enzymatic cell dissociation solution. For 
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membrane preparation, cells were removed from flasks by 
scraping, centrifuged, and then frozen as a pellet at -20 °C until 
required. Before use in a radioligand binding assay, cells were 
defrosted, diluted in Tris buffer (50 mM Tris–HCl and 50 mM 
Tris–base) and homogenized with a hand-held homogenizer. 
 
Radioligand displacement assay  
The assays were carried out with [3H]CP55940 and Tris binding 
buffer (50 mM Tris–HCl, 50 mM Tris–base, 0.1% BSA, pH 7.4), 
total assay volume 500 µl, using the filtration procedure 
described previously.15a,15b Binding was initiated by the 
addition of transfected human CB1 or CB2 CHO cell membranes 
(50 µg protein per well). All assays were performed at 37 °C for 
60 min before termination by the addition of ice-cold Tris 
binding buffer, followed by vacuum filtration using a 24-well 
sampling manifold (Brandel Cell Harvester; Brandel Inc, 
Gaithersburg, MD, USA) and Brandel GF/B filters that had been 
soaked in wash buffer at 4°C for at least 24 h. Each reaction 
well was washed six times with a 1.2 mL aliquot of Tris-binding 
buffer. The filters were oven-dried for 60 min and then placed 
in 3 mL of scintillation fluid (Ultima Gold XR, PerkinElmer, Seer 
Green, Buckinghamshire, UK). Radioactivity was quantified by 
liquid scintillation spectrometry. Specific binding was defined 
as the difference between the binding that occurred in the 
presence and absence of 1 µM unlabelled CP55940. The 
concentration of [3H]CP55940 used in our displacement assays 
was 0.7 nM. The compounds used in this investigation were 
stored as stock solutions of 10 mM in DMSO, the vehicle 
concentration in all assay wells being 0.1% DMSO. 
 
Data Analysis 
Results were calculated as percentage changes from a basal 
level (zero) of [3H]CP55940 binding (in the presence of 
vehicle). GraphPad Prism 5.0 (GraphPad, San Diego, CA) was 
used to construct sigmoidal log concentration-response 
curves, and to calculate values of EC50, Emax, S.E.M and 95% 
confidence intervals. Ki values were calculated as described 
previously.15a,15b,15c P values < 0.05 were considered to be 
significant. 
 
Biological tests on NMDA receptors  
Culturing of primary rat cortical neurons 
Culturing was a modified version of the one reported by 
Furshpan and Potter.18 Brains from E20.5 Sprague Dawley rats 
(sex not determined) were micro-dissected in medium 
containing (in mM): Na2SO4 81.8, K2SO4 30, MgCl2 5.84, CaCl2 
0.252, HEPES 1, Phenol Red 0.001%, 2 D–glucose 20, kynurenic 
acid 1. Cortices were incubated for 40 minutes in papain 
enzyme (10U/mL) (Worthington Biochemical Corporation, 
Lakewood, NJ, USA) and L-cysteine (3.7 mM) then washed and 
triturated in NeuroBasal A medium (supplemented with 1% rat 
serum (Harlan laboratories, Indianapolis, IN, USA), 1 x B–27 
supplement, 1% antibacterial/antimycotic and 1 mM 
glutamine). The cell suspension was diluted in opti–MEM 
(supplemented with 20 mM glucose and 1% 
antibacterial/antimycotic) to give an end concentration of 1 
hemisphere per 14 mL, and 0.5 mL/coverslip plated onto 13 
mm diameter coverslips precoated with poly–D–lysine (1.33% 
w/v in H20) and laminin (0.5% w/v) (Roche, Basel, Switzerland) 
in 24 well plates. Plates were kept at 37 °C in a humidified 5% 
CO2 incubator for 2.5 hours before replacement of the cell 
suspension with supplemented NeuroBasal A. On the fourth 
day in vitro (DIV 4) 1 ml/well of supplemented NeuroBasal A 
containing 9.6 μM cytosine β–D–arabinofuranoside 
hydrochloride was added to the cells. 
 
Whole-cell voltage-clamp recordings 
Recordings were made from DIV7 neurons at room 
temperature (18–21 °C) superfused (at a flow rate of 2 
mL/min) with an external recording solution comprising (in 
mM) NaCl 150, KCl 2.8, HEPES 10, CaCl2 0.5, glucose 10, glycine 
0.05, diethylene triaminepentaacetic acid 0.01, tetrodotoxin 
0.0003; pH 7.35 using NaOH (300–330 mOsm). 50 µM NMDA 
was applied alone for 80 s (to allow response to stabilise), then 
50 µM NMDA was applied along with the compound of 
interest or vehicle alone for 110 s (a lengthy application was 
required due to compound’s slow rate of block). The average 
current during the final 10 s of response to NMDA alone or 
NMDA plus compound was used to calculate percentage 
inhibition. 100 µM of (–)-(R,R)-HU-210F, (+)-(S,S)-HU-211F and 
(+)-(S,S)-HU-211 were used, 10 µM of MK-801 and vehicle was 
1% dimethyl sulfoxide. Application of solutions was controlled 
manually. Patch–pipettes were made from thick–walled 
borosilicate glass (GC150F–7.5, Harvard Apparatus) using a P–
87 puller (Sutter Instruments) to give a resistance of 2–4 MΩ 
when filled with an internal solution containing (in mM): K–
gluconate 141, NaCl 2.5, HEPES 10,  EGTA 11; pH 7.3 with KOH 
(300 mOsm). Currents were recorded using an Axopatch 200B 
amplifier (Molecular Devices). Data were filtered at 5 kHz and 
digitized at 20 kHz via a National Instruments BNC–2090A 
analogue–digital interface (National Instruments, Newbury, 
UK) using WinEDR software (Strathclyde Electrophysiology 
Software). Neurons were voltage– clamped at –60 mV, and 
recordings were rejected if the holding current was greater 
than 150 pA or if the series resistance was greater than 30 MΩ. 
 
Synthetic procedures 
2-(3,5-dimethoxyphenyl)-2-methylpropanenitrile (4)  
To a stirred suspension of sodium hydride (60% in mineral oil, 
677 mg, 16.9 mmol, 3 eq) in dry DMF (5.0 mL) at 0°C was 
added drop-wise a solution of commercially available 2-(3,5-
dimethoxyphenyl)acetonitrile 3 (1.0 g, 5.64 mmol, 1 eq) and 
iodomethane (1.1 mL, 16.9 mmol, 3 eq) in dry DMF (5.0 mL). 
The reaction temperature rose to 25 °C over a 15 min period 
and stirring was continued for 2 h. The reaction mixture was 
quenched with a saturated aqueous NH4Cl solution (5.0 mL) 
and diluted with diethyl ether (10 mL). The organic layer was 
separated and the aqueous layer was extracted with diethyl 
ether (3 x 10 mL). The combined organic layer was washed 
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with water and brine, dried over Na2SO4 and the solvent was 
evaporated under reduced pressure. The crude product was 
purified by flash chromatography on silica gel (Hexane/ EtOAc 
8:2) to give compound 4 (1.1 g, 98%) as a colorless oil. 
Rf 0.35 (Hexane/EtOAc 8:2). 
1H NMR (400 MHz, CDCl3) δ: 1.73 (s, 6H), 3.84 (s, 6H), 6.43 (t, 1 
H, J = 2.2 Hz), 6.63 (d, 2H, J = 2.2 Hz). 
MS (ESI) for C12H15NO2: m/z calculated 206.1 [M
+H]+, 228.1 
[M+Na]+; m/z found (relative intensity) 206.1 [M+H]+ (100), 
228.1 [M+Na]+ (45). 
 
2-(3,5-dimethoxyphenyl)-2-methylpropanal (5)  
To a solution of 4 (1.21 g, 5.90 mmol, 1 eq) in dry DCM (50.0 
mL) at -78°C was added DIBALH (1M solution in hexane, 14.75 
mL, 14.75 mmol, 2.5 eq). The reaction mixture was stirred at 
the same temperature for 1 h and then quenched by drop-
wise addition of potassium sodium tartrate (10% solution in 
water, 20 mL). The resulting mixture was warmed to room 
temperature, stirred vigorously for 1 h, and then diluted with 
EtOAc (20 mL). The organic phase was separated and the 
aqueous phase extracted with EtOAc (3 x 50mL). The 
combined organic layer was washed with water and brine, 
dried over Na2SO4 and the solvent was evaporated under 
reduced pressure. The crude product was purified by flash 
chromatography on silica gel (Hexane/EtOAc 8:2) to give 
aldehyde 5 (1.14 g, 93%) as a colorless oil. 
Rf 0.37 (Hexane/EtOAc 8:2). 
1H NMR (400 MHz, CDCl3) δ: 1.46 (s, 6H), 3.81 (s, 6H), 6.29-6.53 
(m, 3 H), 9.49 (s, 1H). 
13C NMR (100 MHz, CDCl3) δ: 22.6 (x 2C), 50.6, 55.3(x 2C), 98.7, 
105.2 (x 2C), 143.7, 161.2 (x 2C), 201.9. 
MS (ESI) for C12H16O3: m/z calculated 209.1 [M
+H]+; m/z found 
(relative intensity) 209.1 [M+H]+ (100). 
 
5-(bromotriphenyl-λ⁵-phosphanyl)pentan-1-ol (6) 
To a solution of commercially available 5-bromo-1-pentanol 
(2.0 mL, 16.6 mmol, 1 eq) in EtOH (35 mL) was added 
triphenylphosphine (4.35 g, 16.6 mmol, 1 eq) and K2CO3 (2.30 
g, 16.6 mmol, 1 eq) and the mixture was heated at reflux 
overnight. The solvent was evaporated under reduced 
pressure, the crude product was dissolved in toluene (35 mL) 
and the mixture was stirred vigorously at 100 °C for 5 min. The 
mixture was allowed to cool down to r.t. and the crystallized 
phosphonium salt 6 (9.6 g, 74%) was collected by filtration as a 
white crystalline solid.  
MS (ESI) for C23H25OP: m/z calculated 349.2 [M
+H]+; m/z found 
(relative intensity) 349.1 [M+H]+ (100). 
 
(5Z)-7-(3,5-dimethoxyphenyl)-7-methyloct-5-en-1-ol (7) 
To a suspension of phosphonium salt 6 (11.7 g, 27.3 mmol, 5 
eq) in dry THF (130 mL) at 0 °C was added drop-wise LiHMDS 
(1M in THF, 27.3 mL, 27.3 mmol, 5 eq). The mixture was 
warmed to 10 °C and stirred for 30 min to ensure complete 
formation of the orange ylide. A solution of aldehyde 5 (1.1 g, 
5.46 mmol, 1 eq) in THF (15 mL) was added drop-wise to the 
resulting slurry at the same temperature. The reaction was 
stirred overnight at room temperature. The mixture was 
quenched by addition of saturated aqueous NH4Cl (10 mL). The 
organic layer was separated and the aqueous phase was 
extracted with Et2O (3 x 100). The combined organic layer was 
washed with brine, dried over Na2SO4 and the solvent was 
evaporated under reduced pressure. The crude product was 
purified by flash chromatography on silica gel (Hexane/EtOAc 
7:3) to give the alkene 7 (1.4 g, 92%, single diastereoisomer) as 
a colorless oil. 
Rf 0.35 (Hexane/EtOAc 6:4). 
1H NMR (400 MHz, CDCl3) δ: 1.18-1.26 (m, 2H), 1.32-1.40 (m, 
2H), 1.41 (s, 6H), 1.68 (ddd, 2 H, J = 1.7, 7.4, 14.9 Hz), 3.46 (t, 2 
H, J = 6.6 Hz), 3.80 (s, 6H), 5.29 (dt, 1H, J = 7.4, 11.4 Hz), 5.66 
(dt, 1H, J = 1.7, 11.4 Hz), 6.31 (t, 1H, J = 2.3 Hz), 6.58 (d, 2H, J = 
2.3 Hz). 
13C NMR (100 MHz, CDCl3) δ: 25.2, 27.9, 31.3 (x 2C), 32.0, 40.3, 
55.3 (x 2C), 62.7, 96.9, 105.0 (x 2C), 131.0, 139.6, 153.3, 160.4 
(x 2C). 
MS (ESI) for C17H26O3: m/z calculated 279.2 [M
+H]+, 301.2 
[M+Na]+; m/z found (relative intensity) 279.2 [M+H]+ (100), 
301.2 [M+Na]+ (60). 
 
7-(3,5-dimethoxyphenyl)-7-methyloctan-1-ol (8) 
To a solution of 7 (1.39 g, 5.0 mmol, 1 eq) in EtOAc (200 mL) 
was added 10% Pd/C (139 mg), and the resulting suspension 
was stirred vigorously under hydrogen atmosphere overnight 
at room temperature. The catalyst was removed by filtration 
through Celite and the filtrate was evaporated under reduced 
pressure. The crude product was purified by flash 
chromatography on silica gel (Hexane/EtOAc 6:4) to give the 
hydrogenated compound 8 (1.40 g, quantitative yield) as a 
colorless oil.  
Rf 0.35 (Hexane/EtOAc 6:4).  
1H NMR (400 MHz, CDCl3) δ: 1.06-1.14 (m, 2H), 1.21-1.36 (m, 
4H), 1.28 (s, 6H), 1.49-1.54 (m, 2H), 1.56-1.60 (m, 2H), 3.62 (t, 
2 H, J = 6.6 Hz), 3.82 (s, 6H), 6.32 (t, 1H, J = 2.2 Hz), 6.51 (d, 2H, 
J = 2.2 Hz). 
13C NMR (100 MHz, CDCl3) δ: 24.6, 25.6 (x 2C), 29.0, 30.0, 32.8, 
38.0, 44.4, 55.2 (x 2C), 63.0, 96.6, 104.7 (x 2C), 152.5, 160.5 (x 
2C). 
MS (ESI) for C17H28O3: m/z calculated 281.2 [M
+H]+, 303.2 
[M+Na]+; m/z found (relative intensity) 281.2 [M+H]+ (100), 
303.2 [M+Na]+ (40). 
 
5-(8-hydroxy-2-methyloctan-2-yl)benzene-1,3-diol (9)  
To a solution of compound 8 (336 mg, 1.20 mmol, 1 eq) in dry 
Et2O (5.0 mL) and dry THF (0.4 mL) MeMgI (3M in Et2O, 8.0 mL, 
24.0 mmol, 20 eq) was added at 0 °C. The slurry was heated to 
100 °C under reduced pressure, then the residue was heated 
to 170 °C for 1 h under a flux of nitrogen. The cooled reaction 
mixture was quenched with saturated aqueous NH4Cl (10 mL), 
and extracted with EtOAc (5 x 20 mL). The combined organic 
layer was washed with brine, dried over Na2SO4 and the 
solvent was evaporated under reduced pressure. The crude 
product was purified by flash chromatography on silica gel 
(Hexane/EtOAc 1:1) to give the alcohol 9 (212 mg, 70%) as a 
waxy white solid. 
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Rf 0.20 (Hexane/EtOAc 6:4). 
1H NMR (400 MHz, CD3OD) δ: 1.06-1.14 (m, 2H), 1.18-1.34 (m, 
4H), 1.23 (s, 6H), 1.43-1.51 (m, 2H), 1.55-1.59 (m, 2H), 3.52 (t, 
2 H, J = 6.6 Hz), 6.10 (t, 1H, J = 2.2 Hz), 6.31 (d, 2H, J = 2.2 Hz). 
13C NMR (100 MHz, CD3OD) δ: 24.4, 25.4, 28.1 (x 2C), 29.9, 
32.2, 37.1, 44.2, 61.6, 99.3, 104.4 (x 2C), 151.9, 157.6 (x 2C). 
MS (ESI) for C15H24O3: m/z calculated 253.2 [M
+H]+; m/z found 
(relative intensity) 253.2 [M+H]+ (100). 
 
5-(8-fluoro-2-methyloctan-2-yl)benzene-1,3-diol (1)  
To a solution of alcohol 9 (140 mg, 0.55 mmol, 1.0 eq) in DCM 
(10 mL) at -78 °C, DAST (0.1 mL, 0.66 mmol, 1.2 eq) was added 
drop-wise. The reaction was stirred at 0 °C for 15 min, then a 
saturated aqueous solution of NaHCO3 (10 mL) was added. The 
resulting mixture was extracted with DCM (2 x 100 mL), dried 
over Na2SO4, filtered and the solvent was evaporated under 
reduced pressure. The crude product was purified by flash 
chromatography (Hexane/EtOAc 6:4) to give the fluorinated 
compound 1 (70 mg, 50%) as waxy white solid. 
Rf 0.35 (Hexane/EtOAc 6:4). 
1H NMR (400 MHz, CD3OD) δ: 1.07-1.15 (m, 2H), 1.24 (s, 6 H), 
1.24-1.37 (m, 4H), 1.55-1.68 (m, 4H), 4.38 (dt, 2H, JH-H = 6.2, JH-F 
= 47.6 Hz), 6.10 (t, 1H, J = 2.1 Hz), 6.31 (d, 2H, J = 2.1 Hz). 
19F NMR (376 MHz, CD3OD) δ: -219.9 (tt, 1F, J = 24.7, 47.6 Hz). 
13C NMR (100 MHz, CD3OD) δ: 24.3, 24.8 (d, JC-F = 5.4 Hz), 28.1, 
(x 2C), 29.6, 30.1 (d, JC-F = 19.5 Hz), 37.1, 44.1, 83.4, (d, JC-F = 
163.7 Hz), 99.3, 104.3, 151.9, 157.7 (x 2C). 
MS (ESI) for C15H23FO2: m/z calculated 255.2 [M
+H]+, 277.2 
[M+Na]+; m/z found (relative intensity) 255.3 [M+H]+ (100), 
277.2 [M+Na]+ (60). 
 
[(6aR,10aR)-3-(8-fluoro-2-methyloctan-2-yl)-1-hydroxy-6,6-
dimethyl-6H,6aH,7H,10H,10aH-benzo[c]isochromen-9-yl]methyl 
2,2-dimethylpropanoate (10a) 
To a solution of resorcinol 1 (49 mg, 0.19 mmol, 1 eq) and 
pivalate ester 2a (48 mg, 0.19 mmol, 1 eq) in dry DCM (65 mL) 
at -20 °C was added BF3
.OEt2 (0.12 mL, 1.0 mmol, 5.3 eq). The 
mixture was allowed to warm up to room temperature and 
then stirred for 2 h. The mixture was carefully washed with 
brine, over Na2SO4, filtered and the solvent was evaporated 
under reduced pressure. The crude product was purified by 
flash chromatography on silica gel (Hexane/EtOAc 9:1) to give 
compound 10a (51 mg, 55%) as a waxy white solid. 
Rf 0.60 (Hexane/EtOAc 8:2). 
[α]D
27: -112 (c = 0.8, CHCl3). 
1H NMR (400 MHz, CDCl3) δ: 1.08-1.15 (m, 2 H), 1.15 (s, 3H), 
1.23 (s, 6 H), 1.23-1.28 (m, 2 H), 1.25 (s, 9 H), 1.32-1.38 (m, 2 
H), 1.42 (s, 3 H), 1.51-1.56 (m, 2 H), 1.57-1.70 (m, 2 H), 1.83-
1.96 (m, 3H), 2.20-2.32 (m, 1 H), 2.63-2.80 (m, 1 H), 3.38 (dd, 
1H, J = 3.2, 16.6 Hz), 4.42 (dt, 2H, JH-H = 6.2, JH-F = 47.4 Hz), 4.53 
(d, 1H, J = 4.1 Hz), 4.75 (bs, OH), 5.78 (d, 1H, J = 4.5 Hz), 6.25 
(d, 1H, J = 1.6 Hz), 6.41 (d, 1H, J = 1.6 Hz). 
19F NMR (376 MHz, CDCl3) δ: -218.9 (tt, 1F, J = 25.0, 47.4 Hz). 
13C NMR (100M Hz, CDCl3) δ: 18.5, 24.5, 25.0 (d, Jc-F = 5.5 Hz), 
27.3, (x 4C), 27.6, 27.7, 28.7 (x 2C), 29.8, 30.4 (d, Jc-F = 19.3 Hz), 
31.2, 31.6, 37.3, 38.9, 44.3, 44.8, 68.0, 82.2, (d, Jc-F = 163.9 Hz), 
105.4, 108.0, 109.8, 123.3, 134.0, 150.0, 154.5, 154.6, 178.5. 
MS (ESI) for C30H45FO4: m/z calculated 489.3 [M
+H]+; m/z found 
(relative intensity) 489.3 [M+H]+ (100). 
 
(–)-(R,R)-HU-210F 
A solution of the protected ester 10a (47.9 mg, 0.098 mmol, 1 
eq) in dry THF (1.0 ml) was added drop-wise to a suspension of 
LiAlH4 (15.3 mg, 0.39 mmol, 4 eq) in THF (1.0 mL) at 0 °C. The 
reaction mixture was stirred for 2 h and allowed to warm to 
room temperature. The reaction was quenched with water (2 
mL) and extracted with ether (2 x 5 mL).  
The combined organic layer was washed with brine, dried over 
Na2SO4 and the solvent was evaporated under reduced 
pressure. The crude product was purified by flash 
chromatography on silica gel (Hexane/EtOAc 8:2) to give the 
final compound (–)-(R,R)-HU-210F (19.8 mg, 50%, ee 97%) as a 
hygroscopic white solid. The final product was subsequently 
purified by a chiral HPLC (see the Experimental for details) in 
order to obtain (–)-(R,R)-HU-210F enantiomerically pure (ee  
100%). 
Rf 0.30 (Hexane/EtOAc 8:2). 
[α]D
27: -128 (c = 0.4, CHCl3). 
1H NMR (400 MHz, CDCl3) δ: 1.07-1.14 (m, 2 H), 1.12 (s, 3H), 
1.22 (s, 6 H), 1.22-1.28 (m, 2 H), 1.31-1.37 (m, 2 H), 1.41 (s, 3 
H), 1.50-1.54 (m, 2 H), 1.58-1.71 (m, 2 H), 1.82-1.93 (m, 3H), 
2.25 (dd, 1H, J = 4.4, 11.0 Hz), 2.73 (td, 1H, J = 4.6, 10.9 Hz), 
3.47 (dd, 1H, J = 4.0, 15.7 Hz), 4.09 (q, 2H, J = 12.7 Hz), 4.42 (dt, 
2H, JH-H = 6.2, JH-F = 47.4 Hz), 5.54 (bs, OH), 5.77 (d, 1H, J = 4.7 
Hz), 6.25 (d, 1H, J = 1.8 Hz), 6.40 (d, 1H, J = 1.8 Hz). 
19F NMR (376 MHz, CDCl3) δ: -217.8 (tt, 1F, J = 25.0, 47.4 Hz). 
13C NMR (100 MHz, CDCl3) δ: 18.5, 24.5, 25.0 (d, JC-F = 5.5 Hz), 
27.6, 27.7, 28.7 (x 2C), 29.9, 30.4 (d, JC-F = 19.3 Hz), 31.3, 31.5, 
37.3, 44.2, 45.0, 67.1, 76.5, 84.3, (d, JC-F = 163.8 Hz), 105.5, 
107.8, 109.9, 121.5, 138.2, 149.9, 154.5, 154.7. 
MS (ESI) for C25H37FO3: m/z calculated 405.3 [M
+H]+; m/z found 
(relative intensity) 405.3 [M+H]+ (100). 
HRMS calculated for C25H38F1O3: 405.2799, found: 405.2800. 
 
[(6aS,10aS)-3-(8-fluoro-2-methyloctan-2-yl)-1-hydroxy-6,6-
dimethyl-6H,6aH,7H,10H,10aH-benzo[c]isochromen-9-yl]methyl 
2,2-dimethylpropanoate (10b) 
To a solution of resorcinol 1 (42 mg, 0.16 mmol, 1 eq) and 
pivalate ester 2b (41 mg, 0.16 mmol, 1 eq) in dry DCM (60 mL) 
at -20 °C was added BF3
.OEt2 (0.10 mL, 0.85 mmol, 5.3 eq). The 
mixture was allowed to warm up to room temperature and 
then stirred for 2 h. The mixture was carefully washed with 
brine, over Na2SO4, filtered and the solvent was evaporated 
under reduced pressure. The crude product was purified by 
flash chromatography on silica gel (Hexane/EtOAc 9:1) to give 
compound 10b (43 mg, 55%) as a waxy white solid. 
Rf 0.60 (Hexane/EtOAc 8:2). 
[α]D
27: +114 (c = 0.8, CHCl3). 
1H NMR (400 MHz, CDCl3) δ: 1.07-1.17 (m, 2 H), 1.14 (s, 3H), 
1.23 (s, 6 H), 1.23-1.28 (m, 2 H), 1.25 (s, 9 H), 1.31-1.38 (m, 2 
H), 1.42 (s, 3 H), 1.51-1.55 (m, 2 H), 1.58-1.71 (m, 2 H), 1.83-
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1.95 (m, 3H), 2.25-2.39 (m, 1 H), 2.70-2.76 (m, 1 H), 3.38 (dd, 
1H, J = 3.2, 16.6 Hz), 4.42 (dt, 2H, JH-H = 6.2, JH-F = 47.4 Hz), 4.53 
(d, 1H, J = 4.1 Hz), 4.89 (bs, OH), 5.78 (d, 1H, J = 4.5 Hz), 6.25 
(d, 1H, J = 1.6 Hz), 6.41 (d, 1H, J = 1.6 Hz). 
19F NMR (376 MHz, CDCl3) δ: -218.9 (tt, 1F, J = 25.0, 47.4 Hz). 
13C NMR (100 MHz, CDCl3) δ: 18.5, 24.5, 25.0 (d, JC-F = 5.5 Hz), 
27.3, (x 4 C), 27.6, 27.7, 28.7 (x 2 C), 29.8, 30.4 (d, JC-F = 19.3 
Hz), 31.2, 31.6, 37.3, 38.9, 44.3, 44.8, 68.0, 82.2, (d, JC-F = 163.9 
Hz), 105.4, 108.0, 109.8, 123.3, 134.0, 150.0, 154.5, 154.6, 
178.5. 
MS (ESI) for C30H45FO4: m/z calculated 489.3 [M
+H]+; m/z found 
(relative intensity) 489.3 [M+H]+ (100). 
 
(+)-(S,S)-HU-211F  
A solution of the protected ester 10b (40.0 mg, 0.082 mmol, 1 
eq) in dry THF (1.0 ml) was added drop-wise to a suspension of 
LiAlH4 (12.4 mg, 0.33 mmol, 4 eq) in THF (1.0 mL) at 0 °C. The 
reaction mixture was stirred for 2 h and allowed to warm to 
room temperature. The reaction was quenched with water (2 
mL) and extracted with ether (2 x 5 mL).  
The combined organic layer was washed with brine, dried over 
Na2SO4 and the solvent was evaporated under reduced 
pressure. The crude product was purified by flash 
chromatography on silica gel (Hexane/ EtOAc 8:2) to give the 
final compound (+)-(S,S)-HU-211F (16.6 mg, 50%, ee 99%) as a 
hygroscopic white solid. The final product was subsequently 
purified by a chiral HPLC (see the Experimental for details) in 
order to obtain (+)-(S,S)-HU-211F enantiomerically pure (ee 
100%). 
Rf 0.30 (Hexane/EtOAc 8:2). 
[α]D
27: +128 (c = 0.4, CHCl3). 
1H NMR (400 MHz, CDCl3) δ: 1.08-1.15 (m, 2 H), 1.12 (s, 3H), 
1.22 (s, 6 H), 1.22-1.31 (m, 2 H), 1.31-1.37 (m, 2 H), 1.41 (s, 3 
H), 1.50-1.54 (m, 2 H), 1.58-1.71 (m, 2 H), 1.85-1.94 (m, 3H), 
2.26 (dd, 1H, J = 4.4, 11.0 Hz), 2.73 (td, 1H, J = 4.6, 10.9 Hz), 
3.45 (dd, 1H, J = 4.0, 15.7 Hz), 3.92 (bs, OH), 4.12 (q, 2H, J = 
12.7 Hz), 4.42 (dt, 2H, JH-H = 6.2, JH-F = 47.4 Hz), 5.77 (d, 1H, J = 
4.7 Hz), 6.25 (d, 1H, J = 1.8 Hz), 6.40 (d, 1H, J = 1.8 Hz). 
19F NMR (376 MHz, CDCl3) δ: -217.8 (tt, 1F, J = 25.0, 47.4 Hz). 
13C NMR (100 MHz, CDCl3) δ: 18.5, 24.5, 25.0 (d, JC-F = 5.5 Hz), 
27.6, 27.7, 28.7 (x 2C), 29.9, 30.4 (d, JC-F = 19.3 Hz), 31.3, 31.5, 
37.3, 44.2, 45.0, 67.1, 76.5, 84.3, (d, JC-F = 163.8 Hz), 105.5, 
107.8, 109.9, 121.5, 138.2, 149.9, 154.5, 154.7. 
HRMS calculated for C25H38F1O3: 405.2799, found: 405.2800. 
 
1-(8-bromo-2-methyloctan-2-yl)-3,5-dimethoxybenzene (11)  
To an ice-cooled solution of 8 (303 mg, 1.08 mmol, 1 eq) and 
CBr4 (717 mg, 2.16 mmol, 2 eq) in dry CH3CN (12 mL), PPh3 
(482 mg, 1.84 mmol, 1.7 eq) was added in one portion. After 
10 minutes the ice bath was removed and the reaction was 
stirred at room temperature for 1 h. A solution of TEA (0.25 
mL) and MeOH (0.25 mL) was then added to quench the 
reaction. The solvent was evaporated under reduced pressure 
and the crude mixture purified by flash chromatography on 
silica gel (Hexane/EtOAc 98:2) to give 11 (333 mg, 90% yield) 
as a colourless oil. 
Rf 0.52 (Hexane/EtOAc 9:1). 
1H NMR (400 MHz, CDCl3) δ: 1.03-1.14 (m, 2H), 1.17-1.30 (m, 
8H), 1.33-1.40 (m, 2H), 1.50-1.64 (m, 2H), 1.75-1.83 (m, 2H), 
3.36 (t, 2H, J = 6.9 Hz), 3.80 (s, 6H), 6.31 (t, 1 H, J = 2.2 Hz), 6.49 
(d, 2 H, J = 2.2 Hz).  
13C NMR (100 MHz, CDCl3) δ: 24.5, 20.1, 29.0 (x 2C), 29.4, 32.8, 
34.0, 38.0, 44.4, 55.2 (x 2C), 96.6, 104.7 (x 2C), 152.3, 160.5 (x 
2C).  
MS (ESI) for C17H28BrO2: m/z calculated 343.1 [M
+H]+; m/z 
found (relative intensity) 343.0 [M+H]+ (100). 
 
5-(8-bromo-2-methyloctan-2-yl)benzene-1,3-diol (12)  
To a solution of 11 (124 mg, 0.36 mmol, 1eq) in DCE (7 mL) at 
room temperature, BBr3 (1.8 mL of a solution 1M in DCM, 1.8 
mmol, 5 eq) was added and the resulting mixture was stirred 
at reflux for 1.5 h. Then the reaction was cooled to room 
temperature, quenched with water (1 mL) and the solvent 
evaporated. The crude was diluted in water, extracted with 
EtOAc (3 x 10 mL) and the combined organic extracts were 
dried over Na2SO4, filtered and the solvent evaporated under 
reduced pressure. The resulting deprotected compound 12, as 
a dark yellow oil (94 mg, 82% yield), was used for the next 
synthetic step without further purification.  
Rf 0.25 (Hexane/EtOAc 8:2). 
1H NMR (400 MHz, CDCl3) δ: 1.01-1.12 (m, 2H), 1.18-1.27 (m, 
8H), 1.31–1.40 (m, 2H), 1.50-1.56 (m, 2H), 1.71-1.85 (m, 2H), 
3.37 (t, 2H, J = 6.8 Hz), 4.65 (s, 2H), 6.17 (t, 1H, J = 2.2 Hz), 6.37 
(d, 2H, J = 2.2 Hz).  
13C NMR (100 MHz, CDCl3) δ: 24.6, 28.2, 29.0 (x 2C), 29.5, 32.9, 
34.2, 37.9, 44.4, 100.1, 106.0 (x 2C), 153.4, 156.5 (x 2C).  
MS (ESI) for C15H24BrO2: m/z calculated 315.1 [M
+H]+; m/z 
found (relative intensity) 315.0 [M+H]+ (100). 
 
(6aR,10aR)-3-(8-bromo-2-methyloctan-2-yl)-1-hydroxy-6,6-
dimethyl-6H,6aH,7H,10H,10aH-benzo[c]isochromen-9-yl]methyl 
acetate (13) 
To a solution of 12 (58.5 mg, 0.19 mmol, 1 eq) and 2c (39 mg, 
0.19 mmol, 1 eq) in dry DCM (65 mL) at -20 °C, BF3·OEt2 was 
added (0.12 mL, 1.0 mmol, 5.3 eq). The mixture was allowed to 
warm up to room temperature and then stirred for 2 h. The 
mixture was carefully washed with brine, dried over Na2SO4, 
filtered and the solvent was evaporated under reduced 
pressure. The crude product was purified by flash 
chromatography on silica gel (Hexane/EtOAc 9:1) to give 
compound 13 (20 mg, 20% yield) as a dark yellow oil. 
Rf 0.45 (Hexane/EtOAc 8:2). 
[α]D
27: -76 (c = 1.0, CHCl3). 
1H NMR (400 MHz, CDCl3) δ: 1.02-1.15 (m, 5H), 1.18-1.27 (m, 
8H), 1.31-1.41 (m, 5H), 1.47-1.54 (m, 2H), 1.74-1.98 (m, 5H), 
2.07 (s, 3H), 2.19-2.29 (m, 1H), 2.67-2.77 (m, 1H), 3.23-3.45 (m, 
3H), 4.49 (d, 1 H, J = 12.3 Hz), 4.53 (d,1 H, J = 12.3 Hz), 4.78 (s, 
1H), 5.78 (d, 1 H, J = 4.9 Hz), 6.22 (d, 1 H, J = 1.8 Hz), 6.38 (d, 1 
H, J = 1.8 Hz). 
13C NMR (100 MHz, CDCl3) δ: 18.4, 21.0, 24.4, 27.5, 27.6, 28.0, 
28.7, 29.3 (x 2C), 31.1, 31.9, 32.7, 34.0, 37.3, 44.2, 44.6, 68.4, 
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76.5, 105.4, 108.0, 109.7, 124.3, 133.6, 149.9, 154.49, 154.53, 
171.1. 
MS (ESI) for C27H40BrO4: m/z calculated 507.2 [M
+H]+; m/z 
found (relative intensity) 507.2 [M+H]+ (100). 
(6aR,10aR)-3-(8-bromo-2-methyloctan-2-yl)-1-hydroxy-6,6-
dimethyl-6H,6aH,7H,10H,10aH-benzo[c]isochromen-9-yl]methyl 
acetate (14a) 
To a solution of 13 (21.4 mg, 0.042 mmol, 1 eq) and TEA (28 
µL, 0.21 mmol, 5 eq) in DCM (1 mL) at room temperature, 
acetyl chloride (6 µL, 0.084 mmol, 2 eq) was added and the 
reaction was stirred for 30 minutes. Then the solvent was 
evaporated in vacuo and the crude partitioned between DCM 
(3 x 5 mL) and water (3 mL). The combined organic extracts 
were dried over Na2SO4, filtered and the solvent evaporated 
under reduced pressure to afford the desire product 14a (23 
mg, quantitative yield) as a dark yellow oil.  
Rf 0.5 (Hexane/EtOAc 8:2). 
[α]D
27: -75 (c = 1.0, CHCl3). 
1H NMR (400 MHz, CDCl3) δ: 1.04-1.14 (m, 5H), 1.17-1.29 (m, 
8H), 1.30-1.41 (m, 5H), 1.49-1.54 (m, 2H), 1.71-1.99 (m, 5H), 
2.07 (s, 3H), 2.19-2.36 (m, 4H), 2.58-2.66 (m, 1H), 2.93 (dd, 1H, 
J = 4.4, 16.5 Hz), 3.36 (t, 2H, J = 6.9 Hz), 4.42 (d, 1H, J = 12.1 
Hz,), 4.54 (d, 1H, J = 12.1 Hz), 5.80 (d, 1H, J = 4.8 Hz), 6.52 (1H, 
d, J = 1.9 Hz), 6.68 (1H, d, J = 1.9 Hz).  
13C NMR (100 MHz, CDCl3) δ: 18.4, 20.9, 21.2, 24.3, 27.4, 27.6, 
28.0, 28.5, 29.3 (x 2C), 31.4, 31.8, 32.7, 34.0, 37.4, 44.2, 44.4, 
68.3, 77.2 (under solvent residual peak), 112.2, 113.1, 115.2, 
125.2, 132.9, 149.6, 150.14, 154.17, 168.8, 170.8.  
MS (ESI) for C29H42BrO5: m/z calculated 571.2 [M
+Na]+; m/z 
found (relative intensity) 571.2 [M+Na]+ (100). 
RP-HPLC: Luna C18, 5 μm, 100 Å, 250 × 4.6 mm (L × ID); 
injected volume: 20 μL; flow rate: 1 mL/min; mobile phase: 
solvent A = H2O, solvent B = CH3CN; gradient: from 50% B to 
100% B in 15 minutes, then 100% B for 30 minutes. Retention 
Time = 16.1 min. UV absorption was detected at 218 nm. 
Agilent 1200 HPLC system. 
 
(6aR,10aR)-3-(8-bromo-2-methyloctan-2-yl)-9-(hydroxymethyl)-
6,6-dimethyl-6H,6aH,7H,10H,10aH-benzo[c]isochromen-1-ol (14b) 
To a solution of 13 (9.5 mg, 18.7 µmol, 1 eq) in CH3CN (0.5 mL), 
NaOH (0.5 mL of a 4 M aqueous solution) was added. The 
mixture was stirred at 36 °C for 4 h. After this time the acetyl 
group was completely hydrolysed, as shown by TLC analysis, 
the reaction was stopped and the solvent was evaporated 
under pressure. The crude was diluted in water (2 mL), 
extracted with DCM (3 x 5 mL), the combined organic extracts 
were dried over Na2SO4, filtered and the solvent evaporated 
under reduced pressure to afford the desire product 14b (8.7 
mg, quantitative yield) as a dark yellow oil. 
Rf 0.3 (Hexane/EtOAc 7:3). 
[α]D
27: -70 (c = 0.8, CHCl3). 
1H NMR (400 MHz, CDCl3) δ: 1.02-1.14 (m, 5H), 1.17-1.29 (m, 
9H), 1.31-1.42 (m, 5H), 1.48-1.52 (m, 2 H), 1.74-1.94 (m, 5H), 
2.16-2.28 (m, 1H), 2.66-2.75(m, 1H), 3.29-3.49 (m, 3H), 3.96-
4.15 (m, 2H), 4.95 (bs, 1H), 5.74 (d, 1H, J = 4.6 Hz), 6.23 (d, 1 H, 
J = 1.8 Hz), 6.38 (d, 1H, J = 1.8 Hz). 
13C NMR (100 MHz, CDCl3) δ: 18.5, 24.4, 27.6, 28.0, 28.71, 
28.74 (x 2C), 29.4, 29.7, 31.3, 31.6, 32.8, 34.1, 37.3, 44.3, 45.0, 
67.1, 76.5, 105.4, 107.9, 109.9, 121.1, 138.2, 154.5, 154.6.  
MS (ESI) for C25H38BrO3: m/z calculated 465.2 [M
+H]+; m/z 
found (relative intensity) 465.2 [M+H]+ (100).  
RP-HPLC: Luna C18, 5 μm, 100 Å, 250 × 4.6 mm (L × ID); 
injected volume: 20 μL; flow rate: 1 mL/min; mobile phase: 
solvent A = H2O, solvent B = CH3CN; gradient: from 50% B to 
100% B in 15 minutes, then 100% B for 30 minutes. Retention 
Time = 16.1 min. UV absorption was detected at 218 nm. 
Agilent 1200 HPLC system. 
 
(–)-(R,R)-[
18
F]HU-210 
[18F]-Fluoride was produced on a cyclotron by proton 
bombardment of 97% enriched [18O]H2O (Cambridge Isotope 
Laboratories, Inc.) by the 18O(p,n)18F nuclear reaction. The 
silver target (1.1ml) was pressurised to 600psi and irradiated 
with 11MeV protons produced by the CTI/SIEMENS RDS-111 
cyclotron at the John Mallard Scottish PET Centre in Aberdeen. 
Irradiation with a beam current of 29 μA for 7 minutes was 
typically used (3.9 GBq). At the end of bombardment (EOB) the 
target was unloaded within 5 min using argon gas.  
The radiosynthesis of [18F]HU210F was carried out using a 
remotely controlled synthesis module Eckert&Ziegler 
ModularLab synthesizer. Prior to the EOB, vial PO4 was filled 
with KH2PO4 aqueous solution (0.5 mL, 10 mg/mL), and vial 
K222 was filled with Kryptofix 2.2.2 (15 mg) in dry acetonitrile 
(1 mL). Vial ACN was filled with 1 mL of dry acetonitrile and vial 
PREC was filled with precursor 14b (7.7 mg) dissolved in 1 mL 
of dry acetonitrile.  
After the EOB [18F]-fluoride was unloaded and transferred with 
argon gas to the synthesis module, which was contained in a 
lead shielded hot cell. The [18F]-fluoride was subsequently 
isolated using a CHROMAFIX anion exchange cartridge 
(Macherey Nagel, Germany) and then eluted into the reaction 
vessel with the dipotassium hydrogen orthophosphate 
solution (vial PO4). The solution in vial K222 was added to the 
reaction vessel and the azeotropic mixture of water and 
acetonitrile was evaporated under vacuum using a stream of 
helium. The content of the vial ACN was then added and the 
mixture was evaporated under vacuum using a stream of 
helium to ensure formation of the dried complex [K/K222]
18F. 
Precursor 14b in vial PREC was then added and the reaction 
mixture was heated at 100˚C for 15 minutes to produce the 
fluorinated desired product [18F]HU210 (Radiochemical 
conversion by RadioHPLC of 6%). Purification of the crude 
mixture was attempted; an aliquot (100 µL, 120 MBq) of the 
crude mixture was purified by semipreparative HPLC 
(Phenomenex Luna C18(2) column 10x250 mm 100Å 5 µm, 5 
mL/min) affording 4.65 Mbq of [18F]HU210; the collected peak 
was contaminated by approx. 20% of unreacted [18F]fluoride. 
Identity of the product was confirmed by comparison with cold 
reference. (–)-(R,R)-[18F]HU210 production was achieved using 
a non-optimised procedure. 
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